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Articles

Geriatric risk factors for serious COVID-19 outcomes among
older adults with cancer: a cohort study from the COVID-19
and Cancer Consortium
Arielle Elkrief, Cassandra Hennessy, Nicole M Kuderer, Samuel M Rubinstein, Elizabeth Wulff-Burchfield, Rachel P Rosovsky, Karen Vega-Luna,
Michael A Thompson, Orestis A Panagiotou, Aakash Desai, Donna R Rivera, Ali Raza Khaki, Lisa Tachiki, Ryan C Lynch, Catherine Stratton,
Rawad Elias, Gerald Batist, Anup Kasi, Dimpy P Shah, Ziad Bakouny, Angelo Cabal, Jessica Clement, Jennifer Crowell, Becky Dixon,
Christopher R Friese, Stacy L Fry, Punita Grover, Shuchi Gulati, Shilpa Gupta, Clara Hwang, Hina Khan, Soo Jung Kim, Elizabeth J Klein,
Chris Labaki, Rana R McKay, Amanda Nizam, Nathan A Pennell, Matthew Puc, Andrew L Schmidt, Armin Shahrokni, Justin A Shaya,
Christopher T Su, Sarah Wall, Nicole Williams, Trisha M Wise-Draper, Sanjay Mishra, Petros Grivas, Benjamin French*, Jeremy L Warner*,
Tanya M Wildes*, on behalf of the COVID-19 and Cancer Consortium

Summary

Background Older age is associated with poorer outcomes of SARS-CoV-2 infection, although the heterogeneity of
ageing results in some older adults being at greater risk than others. The objective of this study was to quantify the
association of a novel geriatric risk index, comprising age, modified Charlson comorbidity index, and Eastern
Cooperative Oncology Group performance status, with COVID-19 severity and 30-day mortality among older adults
with cancer.
Methods In this cohort study, we enrolled patients aged 60 years and older with a current or previous cancer diagnosis
(excluding those with non-invasive cancers and premalignant or non-malignant conditions) and a current or previous
laboratory-confirmed COVID-19 diagnosis who reported to the COVID-19 and Cancer Consortium (CCC19)
multinational, multicentre, registry between March 17, 2020, and June 6, 2021. Patients were also excluded for unknown
age, missing data resulting in unknown geriatric risk measure, inadequate data quality, or incomplete follow-up
resulting in unknown COVID-19 severity. The exposure of interest was the CCC19 geriatric risk index. The primary
outcome was COVID-19 severity and the secondary outcome was 30-day all-cause mortality; both were assessed in the
full dataset. Adjusted odds ratios (ORs) and 95% CIs were estimated from ordinal and binary logistic regression models.
Findings 5671 patients with cancer and COVID-19 were included in the analysis. Median follow-up time was 56 days
(IQR 22–120), and median age was 72 years (IQR 66–79). The CCC19 geriatric risk index identified 2365 (41·7%)
patients as standard risk, 2217 (39·1%) patients as intermediate risk, and 1089 (19·2%) as high risk. 36 (0·6%) patients
were excluded due to non-calculable geriatric risk index. Compared with standard-risk patients, high-risk patients had
significantly higher COVID-19 severity (adjusted OR 7·24; 95% CI 6·20–8·45). 920 (16·2%) of 5671 patients died
within 30 days of a COVID-19 diagnosis, including 161 (6·8%) of 2365 standard-risk patients, 409 (18·5%) of
2217 intermediate-risk patients, and 350 (32·1%) of 1089 high-risk patients. High-risk patients had higher adjusted
odds of 30-day mortality (adjusted OR 10·7; 95% CI 8·54–13·5) than standard-risk patients.
Interpretation The CCC19 geriatric risk index was strongly associated with COVID-19 severity and 30-day mortality.
Our CCC19 geriatric risk index, based on readily available clinical factors, might provide clinicians with an easy-to-use
risk stratification method to identify older adults most at risk for severe COVID-19 as well as mortality.
Funding US National Institutes of Health National Cancer Institute Cancer Center.
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND
4.0 license.

Introduction
The COVID-19 pandemic, caused by SARS-CoV-2, has
disproportionately affected older adults. Mortality and
complication rates from the disease have been reported
as higher among older adults than younger adults.1
Individuals with cancer who develop COVID-19 are at
risk for more severe outcomes than those without
cancer.2 Among those with cancer, age also increases the
risk of adverse outcomes of infection.3
www.thelancet.com/healthy-longevity Vol 3 March 2022

Because aging is heterogeneous, subgroups of older
adults with cancer will probably be at greater risk than
others for developing adverse outcomes of COVID-19, and
identification of individuals at the highest risk is important
in their clinical care. Studies in the general geriatric
population have shown that the presence of comorbidities
and frailty increase the risk of death and other complications
of COVID-19, as do the presence of comorbidities and poor
performance status in those with cancer.4–6
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Research in context
Evidence before this study
We searched PubMed for studies published from inception up
to Oct 28, 2021, using the key terms “COVID-19” in
combination with “cancer”, “frailty”, and “comorbidities”.
Systematic reviews showed the increased risk of adverse
outcomes of COVID-19 among people of older age, with cancer,
comorbidities, and who were frail. Studies identifying older
adults at greatest risk for adverse outcomes and mortality after
SARS-CoV-2 infection are scarce.
Added value of this study
Among patients aged 60 years or older reported to the
COVID-19 and Cancer Consortium, patients categorised as

Despite this heightened risk of mortality, there is
insufficient understanding of which subpopulations are at
high risk for adverse outcomes of COVID-19.7 The Cancer
and Aging Research Group and the International Society
of Geriatric Oncology released statements on older people
with cancer, but noted that these statements were based
on clinical consensus, not robust evidence.8,9 As a result,
there is an urgent need to determine the effect of
COVID-19 in older adults with cancer and identify those
most vulnerable for adverse outcomes. The primary
objective of this study was to determine whether a
measure of geriatric risk—combining age, comorbidities,
and performance status—could capture risk of severe
clinical outcomes among older patients with cancer and
COVID-19. We also sought to describe the presentation,
complications, and effect of COVID-19 on subsequent
cancer care among older adults with cancer.

Methods

Study design and participants
This was a cohort study of patients reported to the
COVID-19 and Cancer Consortium (CCC19) registry.10,11
The CCC19 registry is accruing deidentified data, from
contributing institutions (appendix pp 1–5), on patients
aged 18 years or older with a current or past history of
haematological malignancy or invasive solid tumour who
have either a laboratory-confirmed SARS-CoV-2 infection
or a presumptive diagnosis of COVID-19. Contributing
institutions in the consortium independently identify
patients and report data through the online REDCap data
collection survey instruments developed by CCC19,
described in detail previously.10 The mechanism of data
collection can be retrospective (after the acute course of
COVID-19) or concurrent, at the discretion of the
respondent, and can be for outpatients or hospitalised
patients.
We describe patients who were reported to the registry
between March 17, 2020, and June 6, 2021, who were
60 years or older at the time of COVID-19 diagnosis, with
a current or previous diagnosis of invasive malignancy
(regardless of date of cancer diagnosis), and a current or

high risk—using a novel geriatric risk index comprising age,
performance status, and comorbidities—had significantly higher
COVID-19 severity, including hospitalisation, need for intensive
care and mechanical ventilation, and death, within 30 days due
to any cause than patients categorised as standard risk or
intermediate risk.
Implications of all the available evidence
Patients with cancer identified as high risk are at higher risk for
severe complications due to COVID-19 than patients
categorised as standard risk or intermediate risk, highlighting
the need for continued protective strategies for this vulnerable
population.

previous laboratory-confirmed diagnosis of SARS-CoV-2
(excluding those with a presumptive diagnosis). All
variables used for the study are data abstracted from
electronic health records by health-care professionals. We
selected people 60 years or older because of the incidence
of geriatric vulnerabilities, a potentially high risk for
adverse outcomes in this age group, and the fact that
previous work in this registry population did not show an
inflection point in outcomes at commonly used but
arbitrary cutoffs for age (such as ≥65 years or ≥70 years).6,12
Patients with non-invasive cancers and premalignant or
non-malignant conditions were excluded. Patients were
also excluded due to unknown age, missing data resulting
in unknown geriatric risk measure, inadequate data
quality (quality score ≥5 according to our previously
published metric11), or incomplete follow-up resulting in
unknown COVID-19 severity (figure 1). The full CCC19
data dictionary is available online. No protected health
information, as defined by the Health Insurance
Portability and Accountability Act of 1996 is collected by
this centralised registry, which was considered exempt
from institutional review board review (VUMC
institutional review board 200467) and was approved by
local institutional review boards at participating sites per
institutional policy, according to the principles of the
Declaration of Helsinki. This study is registered on
ClinicalTrials.gov, NCT04354701, and is ongoing.

Procedures
Presentation of SARS-CoV-2 infection was categorised as
typical, atypical, or none of the listed symptoms.13 Patients
considered to have typical presentations reported one or
more typical symptom, as classified by the US Centers for
Disease Control and Prevention: fever (subjective,
>100·4°F, or >38°C), cough, dyspnoea, myalgia, arthralgia,
headache, anosmia, ageusia, sore throat, rhinorrhoea,
nausea, vomiting, diarrhoea, and abdominal pain.13
Patients considered to have atypical presentations reported
one or more atypical symptoms only: fatigue, altered
mental state, abdominal discomfort, conjunctivitis, and all
other symptoms not previously categorised as typical.
www.thelancet.com/healthy-longevity Vol 3 March 2022
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10 370 complete reports entered into the CCC19 registry

Standard-risk patients

Intermediate-risk
patients

High-risk patients

Outcomes
370 excluded
62 screen failures*
308 not laboratory confirmed
SARS-CoV-2

10 000 laboratory-confirmed cases of SARS-CoV-2 in
the CCC19 registry

4329 excluded
3143 younger than 60 years
672 had insufficient quality data†
478 had incomplete follow-up
36 unknown geriatric risk index

Hospitalised

1122/2365 (47·4%)

1524/2217 (68·7%)

925/1088 (85·0%)

Without oxygen
requirement

351/2358 (14·9%)

406/2205 (18·4%)

221/1080 (20·5%)

With oxygen
requirement

764/2358 (32·4%)

1108/2205 (50·2%)

699/1080 (64·7%)

Admitted to intensive
care unit

319/2350 (13·6%)

478/2193 (21·8%)

249/1060 (23·5%)

Received mechanical
ventilation

211/2357 (9·0%)

305/2204 (13·8%)

128/1076 (11·9%)

Died within 30 days

161/2365 (6·8%)

409/2216 (18·5%)

350/1089 (32·1%)

Died during follow-up

234/2365 (9·9%)

523/2217 (23·6%)

438/1089 (40·2%)

Presentation of infection*
No symptoms

5671 patients included in final analysis

Figure 1: CONSORT diagram and cohort assembly
CCC19=COVID-19 and Cancer Consortium. *In-situ malignancy, precursor
haematologic condition, benign haematologic condition, non-melanoma skin
cancer, non-invasive malignancy, false-positive SARS-CoV-2 test, or non-CCC19
site. †Quality score ≥5.

COVID-19 severity at presentation was categorised as
follows: mild if no hospitalisation indicated, moderate if
hospitalisation indicated, and severe if intensive care unit
(ICU) admission indicated. Presentation of infection was
categorised on the basis of the level of care medically
indicated for COVID-19 as reported in the registry, rather
than only on the level of care administered, to more
accurately reflect the true severity of disease than
categorisation on the basis of patient preference or
institutional policies in the setting of resource limitation.
To define geriatric risk level, we a priori adapted the
simplified International Myeloma Working Group
(IMWG) frailty score, developed in non-COVID-19
patients, adding an intermediate group (appendix p 6).14
The CCC19 registry uses data generally available from
electronic health records and was not specifically designed
to examine frailty or the population of older adults. As
such, no comprehensive geriatric assessment data or
specific data encompassing most extant approaches to
operationalising frailty (ie, Clinical Frailty Scale) are
collected. Of the available registry variables that can be
associated with ageing, performance status and
comorbidities were the most complete and a priori
expected to be prognostic, on the basis of existing
literature. However, rather than simply examining each
variable, we sought to aggregate these ageing-associated
variables into a single index to provide a clinically useful
measure. Adapting the IMWG measure into the CCC19
geriatric risk index allowed us to use a previously
published approach to combining these variables. The
calculation for CCC19 geriatric risk index was based
on age, Charlson comorbidity index (CCI; modified
to exclude cancer diagnosis as a comorbidity, not
www.thelancet.com/healthy-longevity Vol 3 March 2022

332/2365 (14·0%)

307/2217 (13·8%)

125/1089 (11·5%)

Typical

1926/2365 (81·4%)

1788/2217 (80·6%)

865/1089 (79·4%)

Atypical

107/2365 (4·5%)

122/2217 (5·5%)

99/1089 (9·1%)

Severity at presentation†
Mild

1431/2360 (60·6%)

958/2210 (43·3%)

282/1084 (26·0%)

Moderate

736/2360 (31·2%)

964/2210 (43·6%)

625/1084 (57·7%)

Severe

193/2360 (8·2%)

288/2210 (13·0%)

177/1084 (16·3%)

Anti-COVID-19 treatments
Remdesivir

283/2268 (12·5%)

362/2144 (16·9%)

165/1063 (15·5%)

Hydroxychloroquine

306/2268 (13·5%)

384/2144 (17·9%)

226/1063 (21·3%)

Corticosteroids

471/2268 (20·8%)

587/2144 (27·4%)

270/1063 (25·4%)

Other

554/2268 (24·4%)

595/2144 (27·8%)

296/1063 (27·8%)

None

1339/2268 (59·0%)

1059/2144 (49·4%)

488/1063 (45·9%)

Complications
Cardiovascular

401/2354 (17%)

649/2201 (29·5%)

430/1079 (39·9%)

Pulmonary

761/2353 (32·3%)

1052/2207 (47·7%)

663/1081 (61·3%)

Gastrointestinal

88/2347 (3·7%)

104/2195 (4·7%)

49/1074 (4·6%)

Systemic

293/2349 (12·5%)

513/2199 (23·3%)

309/1076 (28·7%)

Acute kidney injury

268/2349 (11·4%)

522/2199 (23·7%)

382/1079 (35·4%)

290/640 (45·3%)

207/462 (44·8%)

77/157 (49·0%)

Delayed

273/640 (42·7%)

189/462 (40·9%)

Stopped

<5/640 (<1%)

8/462 (1·7%)

<5/157 (<3%)

Continued at a lower
dose

<5/640 (<1%)

<5/462 (<1%)

<5/157 (<3%)

Cancer therapy
modification‡

71/157 (45·2%)

Data are n/N (%). Cells with less than five patients were masked (ie, <5) to minimise the risk of re-identification as per
CCC19 policy. Number of patients does not include those with missing data. CCC19=COVID-19 and Cancer Consortium.
*No symptoms: none of the following typical or atypical symptoms reported; typical: at least one typical symptom
reported (fever [subjective, >100·4°F, or >38°C], cough, dyspnoea, myalgia, arthralgia, headache, anosmia, ageusia, sore
throat, rhinorrhoea, nausea, vomiting, diarrhoea, or abdominal pain); atypical: only atypical symptoms reported (fatigue,
altered mental state, abdominal discomfort, conjunctivitis, or all other symptoms). †Mild: no hospitalisation indicated;
moderate: hospitalisation indicated, despite whether it occurred; severe: intensive care unit admission indicated, despite
whether it occurred. ‡Among patients receiving anticancer therapy within 3 months before a COVID-19 diagnosis.
Subsequent cancer therapy modification is only collected on the follow-up forms, such that patients with only baseline
forms filled would not have this information.

Table 1: COVID-19 symptoms, severity, treatments, outcomes, and complications among older adults with
cancer, stratified by geriatric risk index

age-adjusted)15, and Eastern Cooperative Oncology Group
(ECOG)16 performance status as follows: age (≤75 years,
0 points; 76–80 years, 1 point; >80 years, 2 points); CCI
(zero, 0 points; one or two, 1 point; more than two,
2 points); and ECOG performance status (zero, 0 points;
e145
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Standard risk
(n=2365)
Age, years*

Intermediate risk
(n=2217)

High risk
(n=1089)

67 (63–72)

73 (67–79)

60–69

1516 (64·1%)

750 (33·8%)

70 (6·4%)

70–79

822 (34·8%)

949 (42·8%)

268 (24·6%)

27 (1·1%)

518 (23·4%)

751 (68·9%)

≥80

83 (78–87)

Sex
Female

1199 (50·7%)

1012 (45·6%)

500 (45·9%)

Male

1165 (49·3%)

1203 (54·3%)

588 (54 ·0%)

1 (<0·1%)

2 (<0·1%)

1 (<0·1%)

Non-Hispanic White

1356 (57·3%)

1267 (57·1%)

660 (60·6%)

Non-Hispanic Black

416 (17·6%)

437 (19·7%)

198 (18·2%)

Hispanic

303 (12·8%)

234 (10·6%)

86 (7·9%)

Other

247 (10·4%)

240 (10·8%)

130 (11·9%)

43 (1·8%)

39 (1·8%)

15 (1·4%)

Ever

1024 (43·3%)

1213 (54·7%)

625 (57·4%)

Never

1271 (53·7%)

943 (42·5%)

414 (38·0%)

16 (0·7%)

4 (0·4%)

883 (37·3%)

774 (34·9%)

306 (28·1%)

1482 (62·7%)

1436 (64·8%)

783 (71·9%)

Missing data or unknown
Race and ethnicity

Missing data or unknown
Smoking status

Missing data or unknown

8 (0·3%)

Obesity†
Obese
Not obese
Missing data or unknown

0

7 (0·3%)

0

Has dementia
Yes
No
Missing data or unknown

7 (0·3%)
2358 (99·7%)
0

93 (4·2%)

186 (17·1%)

2115 (95·4%)

903 (82·9%)

9 (0·4%)

0

Type of malignancy‡
Solid tumour
Haematological neoplasm

1919 (81·1%)

1844 (83·2%)

896 (82·3%)

530 (22·4%)

478 (21·6%)

254 (23·3%)
583 (53·5%)

Cancer stage
Localised

1314 (55·6%)

1131 (51·0%)

Disseminated

646 (27·3%)

667 (30·1%)

317 (29·1%)

Missing data or unknown

405 (17·1%)

419 (18·9%)

189 (17·4%)

1194 (50·5%)

1033 (46·6%)

503 (46·2%)

Active and responding

271 (11·5%)

237 (10·7%)

111 (10·2%)

Active and stable

445 (18·8%)

405 (18·3%)

208 (19·1%)

Cancer status
Remission or no evidence
of disease

Active and progressing

251 (10·6%)

350 (15·8%)

161 (14·8%)

Unknown

201 (8·5%)

190 (8·6%)

106 (9·7%)

3 (0·1%)

2 (0·1%)

Never or after COVID-19
diagnosis

223 (9·4%)

157 (7·1%)

98 (9·0%)

<2 weeks before COVID-19
diagnosis

611 (25·8%)

544 (24·5%)

242 (22·2%)

2–4 weeks before
COVID-19 diagnosis

204 (8·6%)

181 (8·2%)

71 (6·5%)

1–3 months before
COVID-19 diagnosis

195 (8·2%)

215 (9·7%)

84 (7·7%)

>3 months before
COVID-19 diagnosis

1055 (44·6%)

1035 (46·7%)

534 (49·0%)

49 (2·1%)

55 (2·5%)

Missing data

0

Timing of anti-cancer therapy

Missing data or unknown

50 (4·6%)
(Table 2 continues on next page)
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one, 1 point; two or more, 2 points). ECOG performance
status was determined by the health-care professionals
abstracting from the patient’s chart, and they were
instructed to enter the ECOG performance status at the
time closest to COVID-19 diagnosis, or to note that no
ECOG performance status was recorded within 3 months
before COVID-19 diagnosis if applicable. Based on the
sum of these data patients were categorised as standard
risk (0 or 1 point), intermediate risk (2 or 3 points), or high
risk (4–6 points). To maximise use of the available data, all
patients had a geriatric risk point total calculated; patients
with unknown ECOG performance status were initially
categorised separately on the basis of the available age and
comorbidity data and denoted as belonging to at least that
category, recognising that their level of geriatric risk might
be underestimated. For simplicity of clinical application
and given similarity to the next lowest groups, these at
least categories were consolidated (eg, at least standard
risk was consolidated with standard risk). We analysed the
non-consolidated measure in a sensitivity analysis.
Variables used to define the CCC19 geriatric risk measure
are summarised in the appendix (p 6).

Covariates
Covariates were defined a priori and were sex, race and
ethnicity, smoking status, obesity, dementia, malignancy
type (solid cancer or haematological neoplasm), cancer
status (remission or no evidence of disease vs active or
measurable disease, with active or measurable disease
defined as responding to therapy, stable, or progressing),
anti-cancer therapy within 3 months before COVID-19
diagnosis (any systemic therapy, radiotherapy, and
excluding surgery), country of patient residence (USA or
outside USA), and month of COVID-19 diagnosis
(January to April, 2020; May to August, 2020; September
to December, 2020; January to April, 2021; and
May to June, 2021).

Outcomes
The primary outcome was a six-level ordinal scale of
COVID-19 severity based on a patient’s most severe
reported disease status: none of the following compli
cations; hospitalisation; hospitalisation with oxygen
requirement; ICU admission; requirement for mechan
ical ventilation; and death due to any cause. This scale
was similar to the five-level ordinal variable used in
previous CCC19 analyses, but with the additional level of
hospitalisation with oxygen requirement, to account for
older adults with greater severity than those hospitalised
without oxygen requirement, but not requiring ICU
admission.6 These outcomes were assessed over the
patient’s total follow-up period. The secondary outcome
was death from any cause within 30 days of COVID-19
diagnosis. Primary and secondary outcomes were
assessed in the full dataset.
Predefined exploratory outcomes included symptoms
and severity of COVID-19 at presentation, as well
www.thelancet.com/healthy-longevity Vol 3 March 2022
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as receipt of anti-COVID-19 treatments (including
remdesivir, hydroxychloroquine, and corticosteroids),
major clinical complications (including cardiovascular,
pulmonary, and gastrointestinal complications and acute
kidney injury), and COVID-19 effect on subsequent
cancer care (ie, therapy modifications).

Statistical analysis
All analysis approaches were specified in a statistical
analysis plan before the initiation of the analysis.17
Standard descriptive statistics were used to summarise
baseline demographic and clinical characteristics,
symptoms and severity of COVID-19 at presentation,
rates of anti-COVID-19 treatments, outcomes, clinical
complications, and anti-cancer therapy modifications
among geriatric risk subgroups. Intersections of
COVID-19 symptoms were summarised overall and
among patients aged 80 years or older. Multiple
imputation (ten iterations; missingness rates were <5%)
using additive regression, bootstrapping, and predictive
mean matching was used to impute missing and
unknown data, except unknown ECOG performance
scores and unknown cancer status, which were included
as unknown categories. Imputation was done on the full
dataset before exclusions.
Unadjusted and adjusted odds ratios (ORs) quantifying
the association of geriatric risk with COVID-19 severity
were estimated from ordinal logistic regression models
and 30-day mortality from binary logistic regression
models. Models for COVID-19 severity included an offset
for (log) follow-up time because severity was assessed
throughout patients’ total follow-up period. Covariates
were selected for inclusion in adjusted models on the basis
of the LASSO.18 Multivariable models that included all
covariates (listed above) plus age, modified CCI, ECOG
performance status, and dementia were fit to each imputed
dataset, with the shrinkage penalty estimated from the first
two datasets via cross-validation and averaged. Covariates
with non-zero coefficients in all imputed datasets were
retained; country of patient residence and month of
COVID-19 diagnosis were included as design variables.
Coefficients and SEs from unadjusted and adjusted
models, variance inflation factors, and clinical judgement
were used to assess model stability. Exploratory analyses
with smoothing splines were used to determine the
association of age (as a continuous variable) with outcomes,
which appeared linear. All other covariates were categorical.
The relative importance of each variable was quantified
using its proportion of the model’s χ² statistic, obtained via
analysis of variance. Analyses were done using
R (version 4.0.2), including the Hmisc, rms, ordinalNet,
and glmnet extension packages.

Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report.
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Standard risk
(n=2365)

Intermediate risk
(n=2217)

High risk
(n=1089)

(Continued from previous page)
Intent of recent anti-cancer therapy§
No recent therapy

1292 (54·6%)

1223 (55·2%)

676 (62·1%)

Palliative

511 (21·6%)

554 (25·0%)

264 (24·2%)

Curative

449 (19·0%)

334 (15·1%)

108 (9·9%)

50 (2·1%)

52 (2·3%)

25 (2·3%)
676 (62·1%)

Missing data or unknown

Modality of recent anti-cancer therapy‡§
None

1292 (54·6%)

1223 (55·2%)

Cytotoxic chemotherapy

389 (16·4%)

398 (18·0%)

135 (12·4%)

Targeted therapy

320 (13·5%)

269 (12·1%)

118 (10·8%)

Endocrine therapy

250 (10·6%)

191 (8·6%)

113 (10·4%)

Immunotherapy

119 (5·0%)

154 (6·9%)

59 (5·4%)

Locoregional therapy

222 (9·4%)

211 (9·5%)

71 (6·5%)

Other

35 (1·5%)

32 (1·4%)

18 (1·7%)

Missing data or unknown

63 (2·7%)

54 (2·4%)

16 (1·5%)

2266 (95·8%)

2132 (96·2%)

1005 (92·3%)

99 (4·2%)

85 (3·8%)

84 (7·7%)

Country of residence
USA
Outside USA
Month of COVID-19 diagnosis
January–April, 2020

558 (23·6%)

571 (25·8%)

377 (34·6%)

May–August, 2020

980 (41·4%)

886 (40·0%)

403 (37·0%)

September–December,
2020

493 (20·8%)

401 (18·1%)

154 (14·1%)

January–April, 2021

320 (13·5%)

338 (15·2%)

142 (13%)

10 (0·4%)

14 (0·6%)

9 (0·8%)

4 (0·2%)

7 (0·3%)

4 (0·4%)

May–June, 2021
Missing data or unknown

Data are n (%) or median (IQR). The missing data or unknown category indicates either missingness due to
non-response to optional survey questions or a response of unknown; an unknown category was provided for all
survey questions. *For patients older than 89 years, age was truncated to 90 years. Truncation was done in
concordance with the Health Insurance Portability and Accountability Act of 1996 and to reduce the risk of
re-identifiability. †Patient reported to be obese or to have a body-mass index ≥30 kg/m2. ‡Percentages could sum to
>100% because categories are not mutually exclusive. §Within 3 months before COVID-19 diagnosis.

Table 2: Demographic and clinical characteristics at COVID-19 diagnosis of older adults with cancer,
stratified by geriatric risk index

Results
In total, 5671 patients were included in the final analysis,
with only 36 (0·6% of 5671) patients excluded from the
cohort because of non-calculable geriatric risk index due
to both missing or unknown performance scores and
comorbidities (figure 1). The median age was 72 years
(IQR 66–79); 1296 (22·9%) patients were 80 years or
older. Median follow-up time was 56 days (IQR 22–120).
4659 (82·2%) patients had a solid tumour diagnosis.
Regarding cancer status, 2730 (48·1%) patients had
cancer in remission or no evidence of disease, and
2439 (43·0%) had active malignancy; the remainder had
unknown or missing cancer status. When categorised
using the CCC19 geriatric risk measure, 2365 (41·7%)
patients were standard risk, 2217 (39·1%) were inter
mediate risk, and 1089 (19·2%) were high risk (table 1;
appendix p 7). Smoking and dementia were substantially
more common in high-risk patients than standard-risk
patients (table 2); no other substantial differences were
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Died from any cause
Received mechanical ventilation
Admitted to intensive care unit

Hospitalised with oxygen
Hospitalised without oxygen
None of these complications

Proportion of patients (%)

100

75

50

25

0

Standard risk

Intermediate risk

High risk

Figure 2: Distribution of the primary ordinal COVID-19 severity outcome in
older adults with cancer, stratified by COVID-19 and Cancer Consortium
geriatric risk index
Model

OR* (95% CI)

COVID-19 severity
Intermediate risk
High risk

Unadjusted

2·73 (2·43–3·07)

Adjusted

2·55 (2·27–2·88)

Unadjusted

7·85 (6·74–9·13)

Adjusted

7·24 (6·20–8·45)

Unadjusted

3·71 (3·04–4·53)

30-day mortality
Intermediate risk

3·64 (2·95–4·48)

Adjusted
High risk

11·0 (8·84–13·7)

Unadjusted

10·7 (8·54–13·5)

Adjusted
1

2

4

8

16

OR

Figure 3: Association of COVID-19 and Cancer Consortium geriatric risk index with COVID-19 severity and
30-day all-cause mortality among older adults with cancer
Model for COVID-19 severity adjusted for sex, race and ethnicity, smoking status, obesity, type of malignancy,
cancer status, recent (within 3 months) anti-cancer therapies (cytotoxic chemotherapy, targeted therapy,
endocrine therapy, immunotherapy, locoregional therapy), country of patient residence, and month of COVID-19
diagnosis; all variance inflation factors <1·6. Model for 30-day all-cause mortality adjusted for sex, race and
ethnicity, smoking status, obesity, type of malignancy, cancer status, recent (within 3 months) anti-cancer
therapies (cytotoxic chemotherapy, endocrine therapy, immunotherapy, locoregional therapy), country of patient
residence, and month of COVID-19 diagnosis; all variance inflation factors <1·7. OR=odds ratio. *ORs relative to
standard-risk patients.

observed. Cancer types were distributed similarly across
geriatric risk categories (appendix p 8).
The primary objective of our study was to examine
COVID-19 severity across the different risk groups. Highrisk patients had higher COVID-19 severity as indicated
by a greater burden of hospitalisation with and without
supplemental oxygen, ICU admission, mechanical
ventilation, and death (figure 2) than standard-risk
patients (table 1). 920 (16·2%) of 5671 patients died
within 30 days of a COVID-19 diagnosis, including
161 (6·8%) of 2365 standard-risk patients, 409 (18·5%)
of 2216 intermediate-risk patients, and 350 (32·1%)
of 1089 high-risk patients (table 1). After adjustment for
other factors associated with COVID-19 severity and
30-day mortality, there was a strong significant
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association between the high CCC19 geriatric risk index
and higher COVID-19 severity and higher odds of 30-day
mortality compared to standard-risk patients (adjusted
OR for COVID-19 severity: 7·24, 95% CI 6·20–8·45;
adjusted OR for 30-day mortality: 10·7, 95% CI 8·54–13·5;
figure 3). In a sensitivity analysis, we examined the
subgroups of patients who were initially categorised by
available data into at least a member of the associated
group (eg, at least intermediate risk if they met criteria
for intermediate risk by age and modified CCI but had
unknown ECOG performance scores). The estimated
ORs for the primary outcome among these subgroups
were similar to that among those with complete geriatric
risk measure data, supporting the consolidation of these
adjacent categories for clinical use (appendix p 9).
Associations of other risk factors with COVID-19 severity
and 30-day mortality are provided in the appendix (p 10).
The CCC19 geriatric risk index showed the largest
proportion of the model’s χ² statistic for both COVID-19
severity (48%) and 30-day mortality (52%; appendix p 12).
Among our secondary objectives was to examine
COVID-19 presentation. Few patients presented with only
atypical symptoms (table 1). Cough, fever, fatigue or
malaise, and dyspnoea were the most common symptoms
(figure 4A). Notably, altered mental state was more
common among patients aged 80 years and older
compared to younger patients (figure 4B). Severity of
COVID-19 at presentation varied across geriatric risk
groups, with only 193 (8·2%) of 2360 standard-risk
patients presenting with severe disease, compared with
288 (13·0%) of 2210 intermediate-risk patients and
177 (16·3%) of 1084 high-risk patients. Most patients did
not receive any specific treatment for COVID-19, and
treatments were similar across geriatric risk groups
(table 1).
Complications from COVID-19 were common, with
the most common being pulmonary complications.
High-risk patients had more complications reported than
intermediate and standard risk groups (table 1). Of the
patients for whom cancer therapy status was known and
who were on active anti-cancer therapy within 3 months
before COVID diagnosis, approximately half had
subsequent modification of their therapy (table 1). The
most common cancer therapy modification for those
with available data was delay in cancer therapy, and this
was similar across all risk groups (table 1).

Discussion
In this large study of 5671 older adults with COVID-19
and cancer, we found that the CCC19 geriatric risk index
was associated with poorer outcomes, including clinical
complications, hospitalisation, and mortality. A higher
CCC19 geriatric risk index was significantly associated
with higher COVID-19 severity and 30-day all-cause
mortality after adjustment of major prognostic
confounding factors and explained the greatest amount
of variation in these outcomes compared with all other
www.thelancet.com/healthy-longevity Vol 3 March 2022
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All patients

Intersection size

150

100

50

0
Cough
Fever
Fatigue or malaise
Dyspnoea
Other symptoms
Nausea, vomiting, or diarrhoea
Myalgia or arthralgia
Cold symptoms
Headache
Altered mental state
Anosmia or ageusia
Abdominal pain
Abdominal discomfort
Conjunctivitis

Symptoms
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Atypical
3000
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0
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B

Patients aged ≥80 years old

60

Intersection size

40

20

0
Cough
Fatigue or malaise
Dyspnoea
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Other symptoms
Nausea, vomiting, or diarrhoea
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Figure 4: Presenting symptoms of COVID-19 among older adults with cancer
UpSet plot indicating intersection between symptoms in older adults with cancer in a matrix layout. The bar graph in the lower left corner depicts symptom-level
distribution across each category (typical or atypical). Each row in the dot graph represents a symptom classification; solid dots represent each symptom part of the
intersecting sets. The centre bar graph depicts the number of symptoms in each intersection.
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risk factors. Our results suggest that the CCC19 geriatric
risk index, using a combination of previously studied
poor prognostic factors for COVID-19 mortality,6,10,19,20 can
effectively risk stratify this vulnerable patient population.
Our study examines the relationship between our novel
geriatric risk index and adverse outcomes from COVID-19
among older adults with cancer, as well as the frequency
of atypical presentations in this population. With this
geriatric risk index, we identified that individuals
categorised as high risk had a 10 times greater odds of
death within 30 days than standard-risk patients. Although
data on frailty specifically are not available in this dataset,
frailty is a commonly used perspective to capture ageassociated vulnerability. In a meta-analysis of studies of
frailty and COVID-19, of 23 944 patients with COVID-19 in
the general population, frailty was present in 51% of
patients and was strongly associated with higher mortality
than non-frail patients, with a pooled OR of 2·48 (95% CI
1·78–3·46), regardless of frailty tool used or geographical
location.5 However, operationalising frailty requires
specific data, such as comprehensive geriatric assessment
or objective measures that are rarely available in routine
clinical practice. Thus, the applicability of frailty in realworld clinical care is limited. The CCC19 geriatric risk
index, in contrast, uses information readily available from
routine oncology care (age, comorbidities, and ECOG
performance status) to identify a group with an extremely
high risk for severe outcomes of COVID-19, lending
credence to our approach of combining known risk factors
into a single geriatric risk index.
Given the adverse COVID-19 outcomes observed in
this high-risk population, our study reinforces the need
to focus efforts on SARS-CoV-2 infection prevention
strategies among older adults with cancer, including
vaccination.21–23 Given concerns about vaccine efficacy
among older adults and those with cancer, vaccination is
only one part of a broader mitigation strategy for this
extremely vulnerable population, which must also
include public health measures: social distancing, mask
wearing, and aggressive vaccination of household
contacts. Unfortunately, these public health measures
have their own serious adverse consequences, as older
adults with or without cancer are at risk of poor outcomes
from social isolation, loneliness, physical deconditioning,
and loss of autonomy, which all increase the risk of
depression and anxiety.24–26
Clinicians should remain cognisant of atypical
presentations of COVID-19. Nearly one in ten patients
aged 80 years and older in our cohort presented with only
atypical symptoms. The recognition that older adults
might present with fewer and atypical symptoms of
infection predates the pandemic; in a study of the
presentation of community-acquired pneumonia in older
adults, 639 (20·5%) of 3124 patients older than 65 years
presented with atypical symptoms, and 175 (4·8%)
of 3630 presented with altered mental state.27 In our
study, altered mental state was the sixth most common
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symptom present at diagnosis. Of note, our study
probably underestimated the prevalence of delirium,
because it is under-recognised and under-reported in
clinical practice. In a study that used a standardised
method for identifying acute confusion as a proxy for
delirium in patients with COVID-19, the prevalence of
delirium was 34·6% (45 of 130 patients) in the subgroup
of frail older adults.28
The high prevalence of complications in the high-risk
group in our study is noteworthy and might inform
simple changes in care to prevent complications. For
instance, one in three (35·4%) high-risk older adults in
our cohort developed acute kidney injury (compared with
23·7% in the intermediate-risk group and only 11·4% in
the standard-risk group). Although renal function
naturally declines with age, the acute illness presents a
number of potential threats to renal function, including
haemodynamic and nephrotoxic medications. Adopting a
nephroprotective mindset for these patients, such as
avoiding nephrotoxic medications and contrast for
computed tomography imaging if possible, could be a
simple step to reduce this complication.29
Despite being a large multicentre study examining a
comprehensive cohort of older adults with cancer and
COVID-19, our study has several limitations that are
inherent to its retrospective registry nature. First, the
CCC19 registry was designed to report COVID-19
outcomes with time intervals rather than with precise
timing of COVID-19 diagnosis and cancer-related
outcomes, to meet Health Insurance Portability and
Accountability Act (HIPPA) and general data protection
regulation requirements. Second, COVID-19-specific
death is underspecified, as this variable was included
several months after the inception of the registry and
would lead to high rates of missingness if included in our
study, and this is an important limitation. Given the
diverse mechanisms of pathophysiology resulting from
SARS-CoV-2, accurate attributable cause of death is a
limitation common to most COVID-19 studies. Patients
aged 89 years or older were masked per HIPAA deidentification requirements, such that we cannot examine
subpopulations of patients aged 90 years or older; notably,
272 (5%) of the patients in our analysis fall into this
category. Moreover, as with any registry-based study, there
might be selection bias toward hospitalised patients.30
Similarly, although adjusted analyses were done,
observational studies are subject to selection bias and
unmeasured confounding. Additionally, we used a
simplified geriatric risk measure adapted from a measure
validated in myeloma patients.14 This measure does
not fully approximate the existing approaches to
operationalising frailty, such as the phenotypic frailty
approach, which requires assessment of grip strength or
gait speed31 and which are rarely obtained in routine
practice and are not included in the CCC19 registry.
Another key limitation is that the IMWG score was
validated in patients with haematologic malignancies, and
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our cohort was primarily a cohort of patients with solid
tumours; however, the proportion of patients with solid
tumours versus haematologic malignancies in each risk
group was similar, lending face validity to its application
in this study. Another limitation is possible misclassi
fication of ECOG in older adults when compared with
geriatric assessment, as performance scores have been
shown repeatedly to underestimate the level of
vulnerability in older adults, as even individuals with good
performance scores might have impairments in functional
status and other important domains.32,33 Consequently, the
CCC19 geriatric risk index might not identify at-risk
patients who have ageing-associated vulnerabilities other
than impaired performance scores or comorbidities.
Lastly, the CCC19 geriatric risk index will require external
validation. Despite these limitations, our large study
generates important data and sets the foundation for
further investigation in this large vulnerable population.
Future research questions include the extent to which
vaccines will reduce incidence and severity of COVID-19
in this vulnerable population who might not mount as
robust an immune response to vaccination; these studies
are ongoing, with encouraging initial results with regard
to older adults with cancer.34 Older adults with cancer
should be prioritised for vaccination roll-out.30 It is
unknown how modifications of anti-cancer therapy affect
cancer control, and whether functional decline due to
COVID-19 affects subsequent ability to tolerate cancer
therapy in a group who might already have been at high
risk for toxicity of therapy.
Patients with high-risk geriatric profiles present with
more severe initial presentations and are at greater risk
for death and other adverse sequelae of COVID-19 than
those with standard-risk profiles. Our CCC19 geriatric
risk index, based on readily available clinical factors,
might provide clinicians with an easy-to-use risk
stratification method to identify older adults most at risk
for severe COVID-19 as well as mortality.
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divisions will be made publicly available for any purpose beginning from
6 months and ending a minimum of 36 months after publication of this
Article through the CCC19 website. Individual deidentified patient data
with site identifiers removed and geographical region of patient
residence masked to a level no smaller than USA census divisions will
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independent review committee identified for this purpose. Proposals can
be submitted beginning 6 months and up to 36 months after publication
of this Article through the following REDCap form: https://redcap.link/
CCC19-data-request. To gain access, approved data requestors will need
to sign a data access agreement.
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